Shots:
- TRIUMPH-2 assessed retatrutide (4, 9, or 12mg, QW) vs PBO in 1152 pts with T2D & obesity/overweight, with trial using a stepwise dose-escalation approach at Q4W. Lilly plans to file BLA in Q1’27
- At 80wks., avg. body weight reductions were 12.7% (4mg), 19.1% (9mg), & 20.8% (12mg) vs 4%, plus A1C reduced by 1.4%, 1.6%, & 1.5%, respectively vs 0.2%. Plus, 73.1%, 79.2% & 79% pts reached A1C ≤6.5% vs 26.3%, while A1C <5.7% was achieved by 28.4%, 40% & 39.3% vs 4.4%
- Also, 36.6%, 62.2%, 67.0% vs 6.4% reached ≥15% weight loss, 24% 45.3% & 52% vs 1.5% achieved ≥20% weight loss, while 10.8%, 30.6% & 34.9% achieved ≥25% vs 0.8%. Avg decrease with highest dose were 39.5% in TGs, 19.6% in non-HDL, 10.8 mmHg in systolic BP, 16.9cm in waist circumference & 58.3% in hsCRP
Ref: PRnewswire | Image: Eli Lilly | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
